Markets

NeoGenomics Inc. (NASDAQ: NEO), a leading oncology testing services company, recently announced its second quarter 2024 financial results, demonstrating significant growth despite undergoing notable leadership changes. Here’s an in-depth look at their performance and strategic initiatives. Financial Performance Highlights NeoGenomics reported a robust second quarter, with notable increases in both revenue and profitability. Key…